Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: The multinational, retrospective, observational CATS study

Date

09 Oct 2016

Session

Poster display

Presenters

Antoine Angelergues

Citation

Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372

Authors

A. Angelergues1, A.J. Birtle2, A.C. Hardy-Bessard3, O. Caffo4, S. Le Moulec5, M. Krainer6, A. Guillot7, A. Hasbini8, G. Daugaard9, S. Chowdhury10, D. Spaeth11, P. Beuzeboc12, J. Eymard13, A. Flechon14, J. Alexandre15, F. Priou16, N. Delanoy1, N. El Awadly1, E. Braychenko17, S. Oudard1

Author affiliations

  • 1 Dept. Medical Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 2 Rosemere Cancer Centre, Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, PR2 9HT - Preston/GB
  • 3 Department Of Medical Oncology, Centre Armoricain d'Oncologie, CARIO, 22190 - Plerin/FR
  • 4 Oncology Department, Ospedale Santa Chiara, 38122 - Trento/IT
  • 5 Medical Oncology, HIA Val de Grace/Institut Bergonie, Bordeaux/FR
  • 6 Department Of Medical Oncology, Medizinische Universitaet Wien (Medical University of Vienna), Vienna/AT
  • 7 Loire, Institut de Cancérologie de la Loire, 42271 - Saint Priest en Jarez/FR
  • 8 Medical Oncology, Clinique Pasteur, Brest/FR
  • 9 Department Of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 - Copenhagen/DK
  • 10 Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 11 Oncology, Centre d’Oncologie de Gentilly, 54000 - Nancy/FR
  • 12 Department Of Oncology, Institut Curie, Paris/FR
  • 13 Medical Oncology, Institut Jean Godinot, 51056 - Reims/FR
  • 14 Medical Oncology, Centre Léon Bérard, Lyon/FR
  • 15 Medical Oncology, Hôpital Cochin, 75014 - Paris/FR
  • 16 Department Of Oncohématology, CHD Vendee - Hopital Les Oudairies, La Roche sur Yon/FR
  • 17 Artic (dept. Medical Oncology), Hopital European George Pompidou, 75015 - Paris/FR
More

Resources

Abstract 2749

Background

Optimal sequencing of new androgen-receptor targeted agents (ART) abiraterone and enzalutamide with docetaxel (D) and cabazitaxel (C) is unknown. In this large retrospective cohort of mCRPC patients, we evaluated the impact of 3 different sequences: D -> C-> ART (group 1), or D -> ART -> C (group 2), or ART -> D -> C (group 3)

Methods

Records of 560 consecutive mCRPC patients were retrospectively collected in 31 centres in 7 European countries from Jan 2011 to Jan 2016. Disease history and clinical characteristics at initiation of each therapy were collected. PSA response ≥ 50%, radiological or clinical progression-free survival (PFS) and overall survival (OS) with each treatment sequence were evaluated.

Results

At sequence initiation, patient characteristics were similar between the 3 sequences: median age was 67 years, 95% were ECOG 0-1, 59% had high disease volume, 42.6% had pain and 8% had visceral metastases. Median number of D cycles was 6 in the 3 groups. Median numbers of C cycles were 7, 6 and 5 in groups 1, 2 and 3 respectively. Median duration of follow-up was 33.7, 31.1, and 23.7 months in groups 1, 2 and 3. Main results are provided in the table.

Sequence PSA response ≥50% / Radiological or clinical PFS* OS from Treatment 1*
Treatment 1 Treatment 2 Treatment 3
D- > C- > ART (n = 129) 61% / 11.5 61% / 11.0 37% / 12.4 37.3 [32.4; 45.2]
D- > ART- > C (n = 390) 63% / 11.9 39% / 9.0 38% / 11.3 36.0 [33.4; 39.7]
ART- > D- > C (n = 41) 60% / 7.4 42% / 6.9 31% / 8.9 30.1 [24.3; 52.7]
p value 0.92 /

Conclusions

PSA responses were generally similar for each treatment line in the 3 groups. No significant difference in OS was observed between the 3 sequences in this retrospective cohort. D showed a longer radiological or clinical PFS when given in first line. The activity of C was not influenced by ART. Sequencing should be based on individual disease characteristics and patients' status and preference.

Clinical trial identification

Legal entity responsible for the study

Sponsor ARTIC

Funding

Sanofi and Janssen

Disclosure

A. Angelergues: Consulting fee Sanofi Travel for meeting Astellas and Janssen.

O. Caffo: Speakers bureaus: Astellas, Janssen, Sanofi, Bayer.

S. Le Moulec: Nonremunerative positions of influence (eg, officer, board member, trustee, or public spokesperson): Sanofi, Roche, BMS, Merck.

A. Guillot: Board Pfizer.

D. Spaeth: Consulting fees (or other payment): Sanofi and Janssen.

P. Beuzeboc: Consulting fees (or pther payment): Sanofi, Astellas, Janssen, Bayer, Amgen.

J-C. Eymard: Consulting fees : Sanofi, Novartis, Pfizer, Janssen Astellas.

A. Flechon: Consulting fees (or other payment): Sanofi, Astellas, Ipsen, Janssen, Ferring, Bayer.

J. Alexandre: Consulting fees (or other payment): Roche, Pharmamar, Novartis.

S. Oudard: Consulting fees (or other payment): Sanofi, Bayer, Astellas, Janssen.

All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.